THE CLAIM. Anthropic reports that Claude, using Opus 4.8 and a Mythos Preview, designed protein binders against 14 of 15 targets, with 22 to 35 percent of individual designs binding successfully against a typical 10 to 15 percent, all physically produced and tested by two outside labs, Adaptyv Bio and Twist Bioscience.

THE CHECK. unusually for this beat, the numbers hold. The designs were made and measured by independent evaluators, and the baseline is sourced. What the headline hides is the method. Claude did not invent a protein-design engine. It orchestrated the structure, sequence, and co-folding models the field already uses, asked to produce 30 candidates per target. Its per-design hit rate of 22 to 35 percent, averaged across all 15 targets, beats the loose field average and sits below the specialist best case of 70 to 80 percent, though that figure comes from just two curated targets with pre-filtered designs, so it is not a clean head to head. And Anthropic states plainly that a minibinder is not a standard drug and that a high-affinity binder is only the first step. This is a strong agent-orchestration result being read as a molecular-biology breakthrough.